作者:Yan Shi、Stephen P. O’Connor、Doree Sitkoff、Jing Zhang、Mengxiao Shi、Sharon N. Bisaha、Ying Wang、Chi Li、Zheming Ruan、R. Michael Lawrence、Herbert E. Klei、Kevin Kish、Eddie C.-K. Liu、Steve M. Seiler、Liang Schweizer、Thomas E. Steinbacher、William A. Schumacher、Jeffrey A. Robl、John E. Macor、Karnail S. Atwal、Philip D. Stein
DOI:10.1016/j.bmcl.2011.06.098
日期:2011.12
The design, synthesis and SAR of a novel class of valerolactam-based arylsulfonamides as potent and selective FXa inhibitors is reported. The arylsulfonamide-valerolactam scaffold was derived based on the proposed bioisosterism to the arylcyanoguanidine-caprolactam core in known FXa inhibitors. The SAR study led to compound 46 as the most potent FXa inhibitor in this series, with an IC50 of 7 nM and EC2xPT of 1.7 mu M. The X-ray structure of compound 40 bound to FXa shows that the sulfonamide-valerolactam scaffold anchors the aryl group in the S1 and the novel acylcytisine pharmacophore in the S4 pockets. (C) 2011 Elsevier Ltd. All rights reserved.